Community Homepage
Discussions
Categories
Quicken for Mac
Quicken Lifehub
Quicken Mobile
Quicken on the Web
Quicken for Windows
Support
Quicken Classic
Quicken Simplifi
Getting Started
Community Training FAQs
Using and Improving the Community
Connect and Engage
Announcements & Alerts
Announcements
Alerts, Online Banking & Known Product Issues
Product Ideas
Beta
Home
Quicken Classic for Windows
Investing (Windows)
What are entries for entering Merger of Genomic and Exact Sciences
Ringo22
Merger took place on 11/12/2019 and I have yet to figure out correct entries to match USAA's capital gain of the Genomic shares removed and cost of Exact Sciences shares of added.
Find more posts tagged with
Accepted answers
Tom Young
This is an easy "cash plus stock" transaction.
Basically you sell your Genomic shares against "proceeds" of the cash received plus the "fair market value" of the Exact Sciences shares received. Then you buy the requisite number of Exact Sciences shares at that same "fair market value."
Here's the Form 8937 that describes the transaction:
http://s22.q4cdn.com/877809405/files/doc_downloads/gov_docs/FORM-8937-signed.pdf
and that suggests a "fair market value" of the Exact Sciences shares of $82.39 but check to see what value your broker used in their 1099-B and they don't have to use that same number.
So, first thing to do is to back up you file and then, probably, delete the transactions downloaded from the broker. (I say "probably" because it sounds like they sent you one or more "Removed" actions and what you want to do is to use a "Sold" action.)
Sell your Genomic shares against the total proceeds of actual cash plus fair market value of the Exact Sciences stock. Include the fractional shares you should have received, (I'm assuming there was a "cash in lieu" transaction associated with all this.) This will leave you with a gain, it sounds like, and a bunch of cash in the Account.
Using the same per share fair market value you used in step 1 buy the number of Exact Science shares, including the fractional shares, you should have received based on the number of shares of Genomic you tendered.
Sell the fractional share using the cash in lieu as the proceeds
You should end up with the correct gain on the sale, the correct cash in your Account and the proper number of shares of Exact Sciences properly priced.
All comments
Tom Young
This is an easy "cash plus stock" transaction.
Basically you sell your Genomic shares against "proceeds" of the cash received plus the "fair market value" of the Exact Sciences shares received. Then you buy the requisite number of Exact Sciences shares at that same "fair market value."
Here's the Form 8937 that describes the transaction:
http://s22.q4cdn.com/877809405/files/doc_downloads/gov_docs/FORM-8937-signed.pdf
and that suggests a "fair market value" of the Exact Sciences shares of $82.39 but check to see what value your broker used in their 1099-B and they don't have to use that same number.
So, first thing to do is to back up you file and then, probably, delete the transactions downloaded from the broker. (I say "probably" because it sounds like they sent you one or more "Removed" actions and what you want to do is to use a "Sold" action.)
Sell your Genomic shares against the total proceeds of actual cash plus fair market value of the Exact Sciences stock. Include the fractional shares you should have received, (I'm assuming there was a "cash in lieu" transaction associated with all this.) This will leave you with a gain, it sounds like, and a bunch of cash in the Account.
Using the same per share fair market value you used in step 1 buy the number of Exact Science shares, including the fractional shares, you should have received based on the number of shares of Genomic you tendered.
Sell the fractional share using the cash in lieu as the proceeds
You should end up with the correct gain on the sale, the correct cash in your Account and the proper number of shares of Exact Sciences properly priced.
q_lurker
I agree with
@Tom Young
's assessment. The key phrase from the cited Form 8937 is
The exchange of Genomic Health stock for the Merger Consideration was a
taxable transaction
for U.S. federal income tax purposes. As a result, a holder’s tax basis in each share of Exact Sciences common stock received in the merger will generally equal the fair market value of such share of Exact Sciences common stock as of the completion of the Merger.
Quick Links
All Categories
Recent Discussions
Activity
My Bookmarks
My Discussions
My Drafts
Unanswered
Best Of